Tuesday, October 23, 2018
- 9:00AM-11:00AM
-
Abstract Number: 2387
Resurrecting Triamcinolone Hexacetonide (the Steroid Formerly Known as Aristospan®): Efficacy and Safety of a Compounded Preparation of Triamcinolone Hexacetonide for Intra-Articular Injection in Children with Arthritis
Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis- 9:00AM-11:00AM
-
Abstract Number: 2543
Retention Rate and Safety Data of Biosimilar CT-P13 in Patients with Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry
Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds- 9:00AM-11:00AM
-
Abstract Number: 2139
Retrospective Study: Association of Hydroxychloroquine Use and Hemolytic Anemia in Patients with Low Levels of Glucose-6-Phosphate Dehydrogenase (G6PD)
Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases- 9:00AM-11:00AM
-
Abstract Number: 2526
Revealing and Addressing Knowledge Gaps Regarding Biosimilars in Rheumatology Practice with Targeted Continuing Education and Patient Surveys
Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds- 9:00AM-11:00AM
-
Abstract Number: 2256
Rheumatic Diseases Associated with Neuromyelitis Optica Spectrum Disorders (NMOSD): Prevalence, Clinical, Laboratory and Imaging Characteristics
Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease- 9:00AM-11:00AM
-
Abstract Number: 2332
Rheumatoid Arthritis Effect´s on Bone Mass and Muscle
Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster- 9:00AM-11:00AM
-
Abstract Number: 2551
Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study
Rheumatoid Arthritis – Treatments Poster III: Biosimilars and New Compounds- 9:00AM-11:00AM
-
Abstract Number: 1979
Rheumatoid Arthritis-Associated Genetic Alteration Defines a New Promoter for Peptydil Arginine Deiminase 4 Gene
Genetics, Genomics and Proteomics Poster- 9:00AM-11:00AM
-
Abstract Number: 2051
Rheumatoid Factor Peptide Expression By Quantitative Proteomics Delineates Responsive and Resistant Clones after Treatment of Early Rheumatoid Arthritis
Rheumatoid Arthritis – Etiology and Pathogenesis Poster III- 9:00AM-11:00AM
-
Abstract Number: 2438
Risk and Severity of Adverse Pregnancy Outcomes in Women with Systemic Sclerosis in Taiwan
Reproductive Issues in Rheumatic Disorders Poster- 9:00AM-11:00AM
-
Abstract Number: 2358
Risk Factors for Persistent Discordance in Global Assessment of Rheumatoid Arthritis (RA) Disease Activity between RA Patients and Their Physicians: Analysis Based on a Nationwide RA Database (2011 to 2016)
Patient Outcomes, Preferences, and Attitudes Poster II: Patient Perspectives- 9:00AM-11:00AM
-
Abstract Number: 2276
Risk of Hemorrhagic Strokes in Patients with Adenosine Deaminase 2 Deficiency
Miscellaneous Rheumatic and Inflammatory Diseases Poster III: Sarcoid, Inflammatory Eye Disease, and Autoinflammatory Disease- 9:00AM-11:00AM
-
Abstract Number: 2456
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients in Truven Marketscan Data (Jan 2010–Sept 2015) Treated with Biologic or Conventional Dmards
Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III: Complications of Therapy, Outcomes, and Measures- 9:00AM-11:00AM
-
Abstract Number: 2455
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Biologic and Non-Biologic Dmards